|
Dec 22
|
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
|
|
Dec 18
|
12 Most Promising Cancer Stocks According to Analysts
|
|
Dec 7
|
Why Is Iovance Biotherapeutics (IOVA) Up 53% Since Last Earnings Report?
|
|
Nov 8
|
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2023 Earnings Call Transcript
|
|
Nov 8
|
Why Iovance Biotherapeutics Stock Is Marching Higher Today
|
|
Nov 8
|
Iovance's (IOVA) Meets Q3 Earnings, Lags Sales Estimates
|
|
Nov 7
|
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates
|
|
Sep 18
|
Independent Director of Iovance Biotherapeutics Wayne Rothbaum Buys 28% More Shares
|
|
Sep 15
|
Why Iovance Biotherapeutics Stock Rocketed 13% Higher Today
|
|
Sep 15
|
Iovance (IOVA) Up Despite FDA's Delayed Decision on Melanoma Drug
|
|
Sep 14
|
U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma
|
|
Sep 14
|
Why Shares of Iovance Biotherapeutics Dropped Thursday
|
|
Aug 9
|
Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q2
|
|
Aug 8
|
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates
|
|
Aug 8
|
Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates
|